表紙
市場調査レポート - 78788

世界の肥満症治療薬市場

Booming Global Obesity Drug Market

発行 RNCOS E-Services Pvt. Ltd.
出版日 ページ情報 英文 80 Pages
価格
世界の肥満症治療薬市場 Booming Global Obesity Drug Market
出版日: 2008年12月08日 ページ情報: 英文 80 Pages
概要

2012年までに、20億以上もの人々が過体重に陥り、そのうちの6億人が肥満症となる見通しです。

当レポートでは、世界における肥満症治療薬市場の過去/現在の実績や将来動向の分析、上市済み/開発段階の各種治療薬の評価や主要製品の将来展望を行っており、概略下記の構成で取り上げております。

第1章 アナリストの視点

第2章 世界的な肥満症の蔓延

  • 肥満症の定義
  • 肥満の流行
  • 肥満症治療のコスト
  • 肥満症と慢性疾患と関連性
  • 医療への支出が高い傾向にある肥満症人口

第3章 減量技術と製品

  • 減量手術
  • 脂肪吸引術
  • ダイエット食品・飲料
  • ダイエットセンター
  • ダイエット薬

第4章 肥満治療薬市場

  • 市場機会の評価
  • 主な治療薬
    • Alli
    • Xenical
    • Acomplia
    • Meridia
  • 治験段階の治療薬

第5章 先進国市場における肥満症

  • 米国
  • 日本
  • ドイツ
  • フランス
  • イタリア
  • スペイン

第6章 新興市場における肥満症

  • ロシア
  • インド
  • ブラジル
  • 中国

第7章 成功要因

  • 肥満症人口の増加
  • アンメットニーズ
  • 自意識/自己実現
  • 強力なパイプライン

第8章 リスク要因

  • 治療薬の商業上・開発上の失敗率が高い
  • 消費者の高い要求
  • 償還における課題
  • 副作用

第9章 主要企業プロファイル

  • Abbott Laboratories
  • Roche Holding Ltd
  • Sanofi-Aventis
  • GlaxoSmithKline plc
  • Pfizer Inc.

図表

目次

Abstract

"Booming Global Obesity Drug Market", our latest research on the obesity market, states that the prevalence of obesity is increasing globally at alarming rates. Obesity drugs market has shown a radical growth in recent times but in contrast, the market for weight loss drugs has failed to match this growth. By 2012, it' s expected that more than two billion people will be overweight and 600 Million will be obese, representing immense opportunities for both the markets.

The market for weight loss drugs is characterized by numerous failures. A number of drugs have failed to get approval, some have been recalled, and those that have entered the market either suffer from serious side effects or have just failed to give the desired weight loss results consumers expected from them. Refusal of healthcare authorities to grant reimbursement to these drugs has also impeded the growth. One of the most recent examples can be taken from Sanofi' s Acomplia; the drug was hailed as multibillion blockbuster before it was launched. But Acomplia, like most of its predecessors, failed to have a sufficient benefit to risk ratio and was taken off the market just two and a half years after its launch.

The future of the obesity drugs market, however, may not be so gloomy. This is because the market has high unmet demand, and any drug that manages to provide a high benefit to risk ratio can easily achieve blockbuster status. Moreover, despite some of its recent failures, the obesity drugs pipeline is rich and a large number of drugs are in phase-III and late phase-II trials. If some of these drugs manage to reach the market and posses a strong efficacy and safety profile, they can quickly become billion-dollar blockbusters.

Country-wise, the US is presently the biggest market for weight loss drugs with around 68% of its population either overweight or obese. The US is followed by the UK and other European countries. In future, emerging economies such as China, Russia, India and Brazil are also expected to become a huge market for weight loss products. With China' s obesity and overweight levels touching 665-670 Million in 2015, the country will emerge as the most potential weight loss market.

Our report gives an extensive and objective analysis on the global market for obesity drugs. It identifies the past and current performance of the market, and outlines the future trends shaping the industry. It comprehensively assesses the performance of drugs, both in the market and in developing stage. Based on various present and future indicators, the report evaluates future outlook and performance of key products in the industry. The research can thus give valuable information to manufacturers/investors planning to foray into the obesity drugs market.

Our report provides forecast on

  • Global obesity market
  • Xenical revenue
  • Meridia revenue
  • Alli revenue
  • Global prevalence of obesity
  • Prevalence of obesity in major developed and emerging markets

Profiling on Key Players

This section gives business overview of the key players, including Roche Holding Ltd, Sanofi-Aventis and Pfizer, who are operating in the global obesity drugs market. It also highlights the strengths and weaknesses of each company.

Table of Contents

1. Analyst View

2. The Global Obesity Epidemic

  • 2.1 Defining Obesity
  • 2.2 Prevalence of Obesity
  • 2.3 The Cost of Obesity
  • 2.4 Obesity is Linked to Higher Rates of Chronic Conditions
  • 2.5 Obese Spend Significantly Higher on Healthcare

3. Available Weight-loss Techniques & Products

  • 3.1 Weight-loss Surgery
  • 3.2 Liposuction
  • 3.3 Weight-loss Foods & Drinks
  • 3.4 Diet Centres
  • 3.5 Weight-loss Drugs

4. Obesity Drugs Market

  • 4.1 Market Opportunity Assessment
  • 4.2 Key Weight-loss Drugs
    • 4.2.1 Alli
      • 4.2.1.1 Market Performance
      • 4.2.1.2 Critical Success & Risk Factors
    • 4.2.2 Xenical
      • 4.2.2.1 Market Performance
      • 4.2.2.2 Critical Success & Risk Factors
    • 4.2.3 Acomplia
      • 4.2.3.1 Market Performance
      • 4.2.3.2 Critical Success & Risk Factors
    • 4.2.4 Meridia
      • 4.2.4.1 Market Performance
      • 4.2.4.2 Critical Success & Risk Factors
  • 4.3 Weight-loss Drugs under Clinical Trials

5. Obesity in Developed Markets - A Brief Profile

  • 5.1 US
  • 5.2 Japan
  • 5.3 Germany
  • 5.4 UK
  • 5.5 France
  • 5.6 Italy
  • 5.7 Spain

6. Obesity in Emerging Markets - A Brief Profile

  • 6.1 Russia
  • 6.2 India
  • 6.3 Brazil
  • 6.4 China

7. Critical Success Factors

  • 7.1 Expanding Waistlines
  • 7.2 High Unmet Needs
  • 7.3 Self-Consciousness & Fulfillment
  • 7.4 Strong Pipeline

8. Critical Risk Factors

  • 8.1 High Failure Rate
  • 8.2 High Consumer Demand
  • 8.3 Reimbursement Issues
  • 8.4 Side Effects

9. Key Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 Roche Holding Ltd
  • 9.3 Sanofi-Aventis
  • 9.4 GlaxoSmithKline plc
  • 9.5 Pfizer Inc.

List of Figures:

  • Figure 2-1: Global - Overweight & Obese Adults* (in Million), 2005, 2007 & 2012
  • Figure 2-2: Global - Proportion of Normal, Overweight & Obese Adults in Global Population (%), 2005, 2007 & 2012
  • Figure 2-3: Relation between Obesity & Increasing Chronic Conditions (%)
  • Figure 2-4: Odd Ratios for Selected Physical Conditions Related to Obesity, Aging, Smoking & Drinking
  • Figure 2-5: Relation between Obesity & Increasing Healthcare Cost (%)
  • Figure 3-1: US - Bariatric Surgeries Preformed (in Number), 2003 & 2007
  • Figure 4-1: Global - Obesity Drugs Market* (in Million US$), 2005-2007 & 2012F
  • Figure 4-2: Global - Obesity Drugs Market by Weight-loss Drugs (%), 2007
  • Figure 4-3: Global - Alli Revenues (in Million US$), 2007 & 2012F
  • Figure 4-4: Global - Xenical Revenues (in Million CHF), 2005, 2007 & 2012F
  • Figure 4-5: Global - Acomplia Revenues (in Million Euro), 2006-Q3 2008
  • Figure 4-6: Global - Meridia Revenues (in Million US$), 2006, 2007 & 2012F
  • Figure 5-1: US - Obesity Drugs Market (in Million US$) 2007 & 2012F
  • Figure 5-2: US - Weight-loss Market (in Billion US$), 2006, 2007E & 2012F
  • Figure 5-3: UK - Prescriptions Dispensed for Obesity Drugs (in Number), 1999 & 2006
  • Figure 6-1: Russia - Obesity Drugs Market by Weight-loss Drugs (%), 2006
  • Figure 6-2: Russia - Slimming Food Supplements Market by Product (%), 2006
  • Figure 6-3: India - Obesity Drugs Market (in Million US$), 2005 & 2006
  • Figure 7-1: Comparison of Safety & Efficacy of Obesity Management Approaches

List of Tables:

  • Table 2-1: Classification of Normal, Overweight & Obese on the Basis of BMI
  • Table 3-1: US - Liposuction Statistics (2007)
  • Table 4-1: Alli - Success & Risk Factor Analysis
  • Table 4-2: Xenical - Success & Risk Factor Analysis
  • Table 4-3: Acomplia - Success & Risk Factor Analysis
  • Table 4-4: Meridia - Success & Risk Factor Analysis
  • Table 4-5: Obesity Drugs in Phase-III Clinical Trials
  • Table 4-6: Obesity Drugs in Phase-II Clinical Trials
  • Table 4-7: Obesity Drugs in Phase-I Clinical Trials
  • Table 5-1: US - Overweight & Obesity Statistics (1990, 2000, 2006, 2007E & 2012F)
  • Table 5-2: Japan - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
  • Table 5-3: Germany - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
  • Table 5-4: UK - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
  • Table 5-5: France - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
  • Table 5-6: Italy - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
  • Table 5-7: Spain - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
  • Table 6-1: Russia - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
  • Table 6-2: India - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
  • Table 6-3: Brazil - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
  • Table 6-4: China - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
  • Table 8-1: Potential Side-effects from Commonly Used Obesity Drugs
  • Table 9-1: Abbott Laboratories - Strengths & Weaknesses
  • Table 9-2: Roche Holding Ltd - Strengths & Weaknesses
  • Table 9-3: Sanofi-Aventis - Strengths & Weaknesses
  • Table 9-4: GlaxoSmithKline plc - Strengths & Weaknesses
  • Table 9-5: Pfizer Inc. - Strengths & Weaknesses
Back to Top